DK1244650T3 - Arylamine derivatives and their use as antithelomerase agents - Google Patents

Arylamine derivatives and their use as antithelomerase agents

Info

Publication number
DK1244650T3
DK1244650T3 DK00985339T DK00985339T DK1244650T3 DK 1244650 T3 DK1244650 T3 DK 1244650T3 DK 00985339 T DK00985339 T DK 00985339T DK 00985339 T DK00985339 T DK 00985339T DK 1244650 T3 DK1244650 T3 DK 1244650T3
Authority
DK
Denmark
Prior art keywords
agents
antithelomerase
arylamine derivatives
concerns
arylamine
Prior art date
Application number
DK00985339T
Other languages
Danish (da)
Inventor
Jean-Francois Riou
Abdelazize Laoui
Patrick Mailliet
Jean-Louis Mergny
Francois Lavelle
Odile Petitgenet
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9915031A external-priority patent/FR2801588B1/en
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of DK1244650T3 publication Critical patent/DK1244650T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C07D251/70—Other substituted melamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

The invention concerns cancer therapy and novel anti-cancer agents having a very particular mechanism. The invention also concerns novel chemical compounds and their therapeutic use in humans.
DK00985339T 1999-11-29 2000-11-27 Arylamine derivatives and their use as antithelomerase agents DK1244650T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9915031A FR2801588B1 (en) 1999-11-29 1999-11-29 CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENT
FR0010561 2000-08-11
PCT/FR2000/003310 WO2001040218A1 (en) 1999-11-29 2000-11-27 Arylamine derivatives and their use as anti-telomerase agent

Publications (1)

Publication Number Publication Date
DK1244650T3 true DK1244650T3 (en) 2003-10-20

Family

ID=26212577

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00985339T DK1244650T3 (en) 1999-11-29 2000-11-27 Arylamine derivatives and their use as antithelomerase agents

Country Status (27)

Country Link
EP (1) EP1244650B1 (en)
JP (1) JP2003515604A (en)
KR (1) KR20020058043A (en)
CN (1) CN1402722A (en)
AT (1) ATE243692T1 (en)
AU (1) AU2179001A (en)
BG (1) BG106753A (en)
BR (1) BR0015992A (en)
CA (1) CA2392507A1 (en)
CO (1) CO5251431A1 (en)
CZ (1) CZ20021849A3 (en)
DE (1) DE60003583T2 (en)
DK (1) DK1244650T3 (en)
EA (1) EA200200616A1 (en)
EE (1) EE200200263A (en)
ES (1) ES2202206T3 (en)
HU (1) HUP0204429A2 (en)
IL (1) IL149402A0 (en)
MX (1) MXPA02005276A (en)
NO (1) NO20022528L (en)
PE (1) PE20010912A1 (en)
PL (1) PL355667A1 (en)
PT (1) PT1244650E (en)
SK (1) SK7402002A3 (en)
UY (1) UY26456A1 (en)
WO (1) WO2001040218A1 (en)
YU (1) YU38102A (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU770600B2 (en) 1999-10-07 2004-02-26 Amgen, Inc. Triazine kinase inhibitors
US6977259B2 (en) 2000-01-28 2005-12-20 Astrazeneca Ab Quinoline derivatives and their use as aurora 2 kinase inhibitors
EP1257546A1 (en) 2000-02-17 2002-11-20 Amgen Inc. Kinase inhibitors
AU2001282268A1 (en) * 2000-08-08 2002-02-18 Aventis Pharma S.A. Phenantridine derivatives and their use as anti-telomerase agent
WO2002059110A1 (en) * 2000-12-21 2002-08-01 Glaxo Group Limited Pyrimidineamines as angiogenesis modulators
FR2821355A1 (en) * 2001-02-23 2002-08-30 Aventis Pharma Sa CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENT
US6887873B2 (en) 2001-03-23 2005-05-03 Aventis Pharma S.A. Triazine derivatives and their application as antitelomerase agents
FR2822468B1 (en) * 2001-03-23 2008-06-20 Aventis Pharma Sa CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTI-TELOMERASE AGENT
CO5380035A1 (en) * 2001-03-23 2004-03-31 Aventis Pharma Sa CHEMICAL DERIVATIVES AND THEIR APPLICATION AS AN ANTITELOMERASA AGENT
AU2002314252A1 (en) * 2001-05-28 2002-12-09 Aventis Pharma S.A. Chemical derivatives and the use thereof as an anti-telomerase agent
US6939874B2 (en) * 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
US7112587B2 (en) 2001-09-21 2006-09-26 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7173032B2 (en) 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7163943B2 (en) 2001-09-21 2007-01-16 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7169785B2 (en) 2001-09-21 2007-01-30 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7132423B2 (en) 2001-09-21 2006-11-07 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
CA2468015A1 (en) 2001-11-27 2003-06-05 Merck & Co., Inc. 2-aminoquinoline compounds
AU2003260472A1 (en) * 2002-09-10 2004-04-30 Pharmacia Italia S.P.A. Substituted pyridine derivatives as antitumor agent
WO2004037808A1 (en) * 2002-10-24 2004-05-06 Chong Kun Dang Pharmaceutical Corp. 2 - substituted heterocyclic compounds and antitumor composition comprising the same
FR2850970B1 (en) * 2003-02-07 2006-07-07 Aventis Pharma Sa CHEMICAL DERIVATIVES BINDING VERY SPECIFIC TO G-QUADRUPLEX DNA STRUCTURES AND THEIR APPLICATION AS A SPECIFIC ANTICANCER AGENT
CA2546727C (en) * 2003-11-20 2012-10-02 Children's Hospital Medical Center Gtpase inhibitors and methods of use
US7335770B2 (en) 2004-03-24 2008-02-26 Reddy U5 Therapeutics, Inc. Triazine compounds and their analogs, compositions, and methods
WO2007049057A2 (en) * 2005-10-28 2007-05-03 Iti Scotland Limited Novel fluorescent dyes and uses thereof
US7713987B2 (en) 2005-12-06 2010-05-11 Rigel Pharmaceuticals, Inc. Pyrimidine-2,4-diamines and their uses
KR100761869B1 (en) * 2006-07-07 2007-10-04 김현기 Triazine derivative compound and composition for treating cancer containing them
EP2046763A2 (en) * 2006-07-31 2009-04-15 Praecis Pharmaceuticals Incorporated Aurora kinase inhibitors from an encoded small molecule library
JP5325517B2 (en) * 2007-10-12 2013-10-23 住友化学株式会社 Method for purifying dibenzooxepin compounds
JP2009102249A (en) * 2007-10-22 2009-05-14 Sumitomo Chemical Co Ltd Method for producing crystal of dibenzoxepin compound crystal

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206768D0 (en) * 1992-03-27 1992-05-13 Jarman Michael New compounds for use in the treatment of cancer
US5770613A (en) * 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
JPH1160573A (en) * 1997-08-22 1999-03-02 Nippon Kayaku Co Ltd Triazine derivative and telomerase inhibitor
US6156763A (en) * 1998-02-04 2000-12-05 Board Of Regents, The University Of Texas System Inhibition of human telomerase by a g-quadruplex-interaction compound
DE19812879A1 (en) * 1998-03-24 1999-09-30 Bayer Ag Substituted 2,4-diamino-1,3,5-triazines

Also Published As

Publication number Publication date
WO2001040218A1 (en) 2001-06-07
PE20010912A1 (en) 2001-09-01
PL355667A1 (en) 2004-05-04
ATE243692T1 (en) 2003-07-15
JP2003515604A (en) 2003-05-07
NO20022528D0 (en) 2002-05-28
BG106753A (en) 2003-02-28
BR0015992A (en) 2002-08-06
YU38102A (en) 2004-12-31
MXPA02005276A (en) 2002-11-07
CA2392507A1 (en) 2001-06-07
EP1244650B1 (en) 2003-06-25
UY26456A1 (en) 2001-06-29
CZ20021849A3 (en) 2002-08-14
EE200200263A (en) 2003-06-16
DE60003583T2 (en) 2004-05-13
CN1402722A (en) 2003-03-12
EP1244650A1 (en) 2002-10-02
NO20022528L (en) 2002-05-28
EA200200616A1 (en) 2002-10-31
HUP0204429A2 (en) 2003-04-28
SK7402002A3 (en) 2002-11-06
IL149402A0 (en) 2002-11-10
ES2202206T3 (en) 2004-04-01
CO5251431A1 (en) 2003-02-28
PT1244650E (en) 2003-11-28
AU2179001A (en) 2001-06-12
DE60003583D1 (en) 2003-07-31
KR20020058043A (en) 2002-07-12

Similar Documents

Publication Publication Date Title
DK1244650T3 (en) Arylamine derivatives and their use as antithelomerase agents
DE60112974D1 (en) Carbolinderivate
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
NO20042635L (en) 5-Sulfanyl-HH-1,2,4-triazole derivatives and their use as medicine
NO20060971L (en) Pyridazine derivatives and their use as therapeutic agents
DK1204649T3 (en) Arylmethylcarbonylaminothiazole derivatives and their use as antitumor agents
DK1525177T3 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and use thereof
ATE231872T1 (en) THIAZOLOPYRIMIDE DERIVATIVES
DE60216233D1 (en) Carbolinderivate
MXPA03002911A (en) Chemical compounds.
WO2002096903A3 (en) Chemical derivatives and the use thereof as an anti-telomerase agent
IS7137A (en) Combination treatment for the treatment of cancer
DK1097173T3 (en) Use of IL-2 peptides and derivatives thereof as therapeutic agents
SE0101932D0 (en) Pharmaceutical combinations
MXPA02012076A (en) Chemical compounds.
MXPA02012659A (en) Chemical compounds.
SE9904377D0 (en) Pharmaceutical combinations
WO2002070469A3 (en) Selective pde3b inhibitors and use of the same in therapy
DE60112960D1 (en) CONDENSED PYRIDOINDOL DERIVATIVES
MY130957A (en) Triazine derivatives and their application as antitelomerase agents
DE60315288D1 (en) CYANOGUANIDINE PRODRUGS
MXPA02012472A (en) Chemical compounds.
WO2002039958A3 (en) Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
CO5021190A1 (en) THERAPEUTIC AGENTS